8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): November 21, 2007

                                Greatbatch, Inc.
                                ----------------
             (Exact name of registrant as specified in its charter)


        Delaware                        1-16137                  16-1531026
        --------                        -------                  ----------
(State or other jurisdiction    (Commission File Number)       (IRS Employer
    of incorporation)                                        Identification No.)


                   9645 Wehrle Drive, Clarence, New York 14031
                   -------------------------------------------
              (Address of principal executive offices and Zip Code)


       Registrant's telephone number, including area code: (716)-759-6901

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))



Section 1 - Registrant's Business and Operations

Item 1.01 Entry into a Material Definitive Agreement

     On November 21, 2007, Greatbatch Ltd., a New York corporation
("Purchaser"), Greatbatch, Inc., a Delaware corporation ("Greatbatch") and the
shareholders of P Medical Holding SA, a societe anonyme organized and existing
under the laws of Switzerland ("Precimed"), entered into a purchase agreement
(the "Purchase Agreement") pursuant to which, subject to the satisfaction or
waiver of the conditions therein, Purchaser will acquire all of the shares of
Precimed and Precimed's right to acquire the operations of another company in
the orthopedic industry. Under the terms of the Purchase Agreement, the
aggregate purchase price will be approximately $125 million in cash, plus a
contingent payment of up to approximately $10.0 million based on Precimed's 2008
earnings performance. The Purchase Agreement also provides for a payment of
approximately $1.4 million in the event of a breach of contract by either party
that results in a termination of the agreement prior to closing. Approximately
$7.0 million will be placed in escrow to reimburse Purchaser for any
indemnification claims as defined in the Purchase Agreement.


Section 8 - Other Events

Item 8.01 Other Events

     On November 26, 2007, Greatbatch issued a press release, a copy of which is
attached hereto as Exhibit 99.1, announcing that it has signed a definitive
agreement to acquire Precimed, a leading technology-driven supplier to the
orthopedic industry.

     On November 28, 2007, Greatbatch issued a press release, a copy of which is
attached hereto as Exhibit 99.2, describing the Company's expanded strategic
direction and providing preliminary financial estimates for 2008.


Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No.     Title of Exhibit
- -----------     ----------------

  99.1          Press Release of Greatbatch, Inc. dated November 26, 2007
  99.2          Press Release of Greatbatch, Inc. dated November 28, 2007



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                        GREATBATCH, INC.

Date: November 27, 2007                 By: /s/ Thomas J. Mazza
                                            ------------------------------------
                                            Thomas J. Mazza
                                            Senior Vice President and Chief
                                                Financial Officer

EX-99.1

                                                                    Exhibit 99.1


      Greatbatch Signs Definitive Agreement to Acquire Precimed

    Establishes Greatbatch as a Leading Supplier to Orthopedic OEMs

      Provides Diversification into $20 Billion Orthopedic Market

             Expands Global Presence into Europe and Asia


    CLARENCE, N.Y.--(BUSINESS WIRE)--Nov. 26, 2007--Greatbatch, Inc.
(NYSE: GB) announced today that it is has signed a definitive
agreement to acquire Precimed, a leading technology-driven supplier to
the orthopedic industry. This agreement also includes Precimed's
contract to acquire the operations of another company in the
orthopedic industry. The combined transaction will establish
Greatbatch as one of the top three suppliers to Orthopedic OEMs. This
transaction significantly diversifies Greatbatch's market presence
into the orthopedic market and establishes the company as a leading
OEM supplier to multiple market verticals, including the Cardiac
Rhythm Management, Vascular, Neurostimulation and Specialty Commercial
Power markets. Under terms of the agreement, the aggregate purchase
price will be approximately $125 million depending on closing
adjustments.

    Precimed is located in Orvin, Switzerland & Exton, PA, with
manufacturing operations throughout Switzerland & Indiana and sales
offices in Japan, Asia & the United Kingdom. Its products, including
instrumentation for hip & knee replacement, trauma and spine are sold
worldwide to leading orthopedic customers. Precimed's pending
acquisition will align them closer to their OEM customers and extend
its offerings to a broader range of orthopedic products. Precimed is
well known in the industry for outstanding quality and innovative
products in growing market segments such as minimally invasive
surgery, resurfacing, computer-aided surgery, RFID tracking and
disposable instruments. The company has a history of engineering
excellence in the design custom proprietary products and currently has
over 90 patents & pending patents.

    Thomas J. Hook, Greatbatch's President & CEO, commented, "This
acquisition supports our strategic vision to be a key global component
supplier to the medical device industry. Precimed has a breadth of
production capabilities, technology and relationships with orthopedic
OEMs that provides a key competitive differentiator in the market.
Combined with Precimed's capability to design, sell and manufacture
in-house turnkey solutions (instruments, implants and cases) enables
Greatbatch to obtain a growth platform in a large and growing
implantable market segment.

    "This transaction serves as Greatbatch's entree into the
attractive orthopedic market segment. The orthopedic market is a $20+
billion device industry growing at approximately 10 percent annually
with the outsourcing market expected to grow even faster. This
transaction provides Greatbatch with significant market, geographic
and customer diversification while expanding relationships with
existing Greatbatch customers.

    "Over the past several years, Precimed has been transformed into a
major supplier to the orthopedic market under the leadership of
Patrick Berdoz and John Ayliffe. An extremely important benefit of
this transaction is that Patrick and John have agreed to become part
of the Greatbatch Management team, bringing with them their enthusiasm
to continue growing the orthopedic business."

    Patrick Berdoz stated, "John Ayliffe and I are proud of the
organization we have established and believe that the combination with
Greatbatch will accelerate our growth in the orthopedic market.
Greatbatch is an outstanding organization that shares our passion for
technology innovation and customer service. I am looking forward to
the exciting opportunities this combination presents."

    Under the terms of the agreement, Greatbatch will acquire the
shares of Precimed, along with the assets of Precimed's pending
acquisition for approximately $125 million in cash, plus an additional
earnings-based contingent cash payment of up to approximately $10
million based on 2008 earnings performance. The company will utilize
cash on hand and availability under its revolving credit agreement to
fund these transactions. Both transactions are expected to close in
early 2008.

    Greatbatch's 2008 annual orthopedics revenues are anticipated to
be in the range of $100 to $120 million. Excluding the impact of the
acquisition related charges, such as in-process research development
and integration costs, Greatbatch expects this acquisition to be
neutral to GAAP EPS in 2008. In 2009 and thereafter, Greatbatch
anticipates the transaction will be accretive to GAAP earnings per
share.

    Forward-Looking Statements

    Some of the statements in this press release and other written and
oral statements made from time to time by the Company and its
representatives are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and section 21E
of the Securities Exchange Act of 1934, as amended, and involve a
number of risks and uncertainties. These statements can be identified
by terminology such as "may," "will," "should," "could," "expects,"
"intends," "plans," "anticipates," "believes," "estimates,"
"predicts," "potential" or "continue," or the negative of these terms
or other comparable terminology. These statements are based on the
Company's current expectations. The Company's actual results could
differ materially from those stated or implied in such forward-looking
statements. Risks and uncertainties that could cause actual results to
differ materially from those stated or implied by such forward-looking
statements include, among others, the following matters affecting the
Company: the Company's ability to complete on a timely basis, or at
all, the above mentioned acquisitions and the risks arising from
assumed and unknown liabilities associated with those acquisitions,
dependence upon a limited number of customers; customer ordering
patterns; product obsolescence; inability to market current or future
products; pricing pressure from customers; our ability to timely and
successfully implement our cost reduction and plant consolidation
initiatives; reliance on third party suppliers for raw materials,
products and subcomponents; fluctuating operating results; inability
to maintain high quality standards for our products; challenges to our
intellectual property rights; product liability claims; inability to
successfully consummate and integrate acquisitions; unsuccessful
expansion into new markets; competition; inability to obtain licenses
to key technology; regulatory changes or consolidation in the
healthcare industry; and other risks and uncertainties described in
the Company's Annual Report on Form 10-K and in other periodic filings
with the Securities and Exchange Commission. The Company assumes no
obligation to update forward-looking information in this press release
whether to reflect changed assumptions, the occurrence of
unanticipated events or changes in future operating results, financial
conditions or prospects, or otherwise.

    About Greatbatch, Inc.

    Greatbatch, Inc. (NYSE: GB) is a leading developer and
manufacturer of critical components used in medical devices for the
cardiac rhythm management, neurostimulation, vascular and
interventional radiology markets. Additionally, Electrochem Commercial
Power, a subsidiary of Greatbatch, is a world leader in the design and
manufacture of electrochemical cells, battery packs and wireless
sensors for demanding applications such as oil and gas exploration,
pipeline inspection, military, asset tracking, oceanography, external
medical and seismic surveying. Additional information about the
Company is available at www.greatbatch.com.


    CONTACT: Greatbatch, Inc.
             Anthony W. Borowicz, 716-759-5809
             Treasurer and Director, Investor Relations
             tborowicz@greatbatch.com

EX-99.2

                                                                    Exhibit 99.2

              Greatbatch Provides Preliminary Financial
                          Estimates for 2008


    CLARENCE, N.Y.--(BUSINESS WIRE)--November 28, 2007--Greatbatch,
Inc. (NYSE: GB) recently presented at Investor Conferences in New York
City where Thomas J. Hook, President and Chief Executive Officer,
described the Company's expanded strategic direction, which is based
on growth through Innovation, Investment and Acquisition. These
presentations can be accessed on the Company's website at
www.greatbatch.com. The key takeaways from the Conferences are
described below:

    Over the past 3 years, Greatbatch has delivered strong revenue and
profitability growth. Initiatives focused on key customer
opportunities, and operational consolidations of multiple locations
into new manufacturing facilities, have delivered growth above the
rates of the underlying markets. Both medical & commercial business
segments have significant opportunities for further improvement but
CRM industry concentration remains a risk given the market dynamics.
Greatbatch's strategic plan encompasses the continued growth in the
CRM market, but also enhances these plans with aggressive investment &
acquisition initiatives to diversify the company in implantable
medical markets and specialty commercial power applications.
Technology will remain the key focal point for each of the market
opportunities. The acquisitions of Biomec, Enpath, Quan Emerteq &
Precimed in medical and IntelliSensing & EAC in commercial have
positioned Greatbatch more broadly within the strategic markets
served. The execution of these strategic initiatives has established
Greatbatch as a leader in four market verticals; CRM,
Neurostimulation, Vascular, Orthopedics and Specialty Commercial
Power. Innovation and investment initiatives have also contributed
critical technologies to Greatbatch's product portfolio. Following
this acquisition period, Greatbatch has sound financials, including
continued revenue & profitability growth, strong cash flow generation
and a conservative capitalization structure. 2008 will commence a
period of concentrated integration activities for the various
acquisitions & investments and will dovetail nicely into the current
Greatbatch initiatives and leadership team. Several recognized
industry leaders have joined the Greatbatch executive team following
the acquisitions. The new leaders will provide Greatbatch the
experience and balance to successfully grow and integrate multiple
businesses. The combined Greatbatch management team is highly
motivated to deliver revenue & profit growth and is enthusiastic about
the future opportunities.

    Based on the anticipated completion of the announced acquisitions,
the Company provided preliminary 2008 financial estimates, as follows:

    2008 Preliminary Financial Estimates

    --  Sales $500 - $550 Million

    --  Adjusted Operating Income Margin 11% - 13%

    --  Adjusted EBITDA Margin 21% - 23%

    --  Targeting Improvements in Operating Margin of 200 Basis Points
        Per Year for the Next Three Years

    Note: Adjusted Operating and EBITDA exclude the impact of the
acquisition related charges, such as in-process research development
and integration costs. This financial information is a preliminary
estimate based upon the closing of the recently announced Precimed
acquisition in early 2008. These estimates shown are subject to change
based upon the results of purchase price accounting, which will not be
finalized until 2008. Additionally, these estimates exclude
integration costs and anticipated synergies, which will not be fully
determined until the first quarter of 2008.

    Forward-Looking Statements

    Some of the statements in this press release and other written and
oral statements made from time to time by the Company and its
representatives are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and section 21E
of the Securities Exchange Act of 1934, as amended, and involve a
number of risks and uncertainties. These statements can be identified
by terminology such as "may," "will," "should," "could," "expects,"
"intends," "plans," "anticipates," "believes," "estimates,"
"predicts," "potential" or "continue," or the negative of these terms
or other comparable terminology. These statements are based on the
Company's current expectations. The Company's actual results could
differ materially from those stated or implied in such forward-looking
statements. Risks and uncertainties that could cause actual results to
differ materially from those stated or implied by such forward-looking
statements include, among others, the following matters affecting the
Company: dependence upon a limited number of customers; customer
ordering patterns; product obsolescence; inability to market current
or future products; pricing pressure from customers; our ability to
timely and successfully implement our cost reduction and plant
consolidation initiatives; reliance on third party suppliers for raw
materials, products and subcomponents; fluctuating operating results;
inability to maintain high quality standards for our products;
challenges to our intellectual property rights; product liability
claims; inability to successfully consummate and integrate
acquisitions; unsuccessful expansion into new markets; competition;
inability to obtain licenses to key technology; regulatory changes or
consolidation in the healthcare industry; and other risks and
uncertainties described in the Company's Annual Report on Form 10-K
and in other periodic filings with the Securities and Exchange
Commission. The Company assumes no obligation to update
forward-looking information in this press release whether to reflect
changed assumptions, the occurrence of unanticipated events or changes
in future operating results, financial conditions or prospects, or
otherwise.

    About Greatbatch, Inc.

    Greatbatch, Inc. (NYSE: GB) is a leading developer and
manufacturer of critical components used in medical devices for the
cardiac rhythm management, neurostimulation, vascular and
interventional radiology markets. Additionally, Electrochem Commercial
Power, a subsidiary of Greatbatch, is a world leader in the design and
manufacture of electrochemical cells, battery packs and wireless
sensors for demanding applications such as oil and gas exploration,
pipeline inspection, military, asset tracking, oceanography, external
medical and seismic surveying. Additional information about the
Company is available at www.greatbatch.com.


    CONTACT: Greatbatch, Inc.
             Anthony W. Borowicz, 716-759-5809
             Treasurer and Director, Investor Relations
             tborowicz@greatbatch.com